Long‐term survivors of childhood, adolescent and young adult non‐Hodgkin lymphoma. (3rd February 2019)

• Record Type: Journal Article
• Authors: Ehrhardt, Matthew J.; Hochberg, Jessica; Bjornard, Kari L.; Brinkman, Tara M.
• Other Names: Cairo Mitchell S. guestEditor.
• Is Part Of: British journal of haematology. Volume 185:Number 6(2019)
• Page Start: 1099
• Page End: 1110
• Publication Date: 2019-02-03
• Subjects: non‐Hodgkin lymphoma -- late effects of therapy -- paediatric oncology; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.15775
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Progress in overall survival rates for childhood non‐Hodgkin lymphoma (NHL) can be largely attributed to effective development and conduct of a number of international treatment studies. Knowledge gained from these studies has shifted the treatment paradigm from a "one‐size fits all" strategy to a histologically dependent approach. More specifically, many now adhere to a risk‐stratified approach, prescribing cumulative doses and intensities of chemotherapeutic exposures based upon the aggressiveness of disease. Moreover, recognition that high cure rates could be achieved without the use of radiation has eliminated the use of this modality in frontline settings for the majority of newly diagnosed children. These changes have contributed to the emergence of a heterogeneous group of NHL survivors. As the number of NHL survivors continues to increase, providers will encounter a wide spectrum of individuals whose risk for long‐term complications are accordingly diverse. The following review summarizes the existing literature surrounding late effects, such as chronic health conditions, functional and neurocognitive performance outcomes, and health‐related quality of life, that are unique to NHL survivors, as well as those extrapolated from the broader childhood cancer survivor population.